News & Resources
The Cancer Immunotherapy Consortium embraces communication and collaboration among its members and among other like-minded associations that strive to bring effective immune-based cancer treatments to more patients.
CIC members contribute to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
We invite you to browse our library of publications, news releases, and e-newsletters.
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.
April 23, 2013
The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of the Cancer Research Institute today announced a publication discussing the results of a unique collaborative vetting process which has now led to publication guidelines that increase transparency of immune response assessments.
July 25, 2012
The Association for Cancer Immunotherapy Immunoguiding Program and the Cancer Immunotherapy Consortium of CRI published a joint paper discussing recent results of independent international, cross-laboratory immune assay harmonization studies.
November 8, 2011
Drs. James P. Allison, chair of the immunology program at Memorial Sloan-Kettering Cancer Center, and Axel Hoos, medical lead in immunology/oncology at Bristol-Myers Squibb, have been named directors of the CRI Cancer Immunotherapy Consortium (CIC), the premier academic-industry association dedicated to accelerating development of safe and effective cancer immunotherapies to patients.
November 7, 2011
The Cancer Immunotherapy Consortium of the Cancer Research Institute and the Association for Cancer Immunotherapy have issued a joint white paper, published in the October 13 issue of Nature Biotechnology, outlining a comprehensive roadmap that promises to help improve and facilitate the path forward in the development of novel immunotherapies for cancer.
October 17, 2011